ArticleWorld journal of urology2023
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors.
Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05078359 (Optimizing Positive Predicting Value of Prostate Magnetic Resonance Imaging), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing Positive Predicting Value of Prostate Magnetic Resonance Imaging: Retrospective Multi-institutional Study Using the PRostate Mri Outcome Database (PROMOD)
Who cites it
10 citing papers in PubMed, 8 citations in OpenAlex.
- Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.Prostate cancer and prostatic diseases · 2026Article
- Head-to-head comparison of MRI-based PI-RR scoring system and 68 Ga-PSMA-PET/CT: enhancing prostate cancer recurrence detection after radical prostatectomy.La Radiologia medica · 2026Article
- The Impact of Dutasteride Treatment on Subsequent Multiparametric Prostate Magnetic Resonance Imaging Sequences and PI-RADS Score in Patients With PI-RADS 3 Lesions in the Transitional Zone.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.BJU international · 2026Article
- The effect of 5-alpha reductase inhibitors on the detection of prostate cancer with multiparametric magnetic resonance imaging and prostate biopsy.Croatian medical journal · 2024Article
- External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors.World journal of urology · 2024Article
- What the urologist needs to know before radical prostatectomy: MRI effective support to pre-surgery planning.La Radiologia medica · 2024Review
- Development and validation of a clinical-radiomics model for prediction of prostate cancer: a multicenter study.World journal of urology · 2024Article
- Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection.Biomolecules · 2024Article
- Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".World journal of urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe primary aim of this study was to evaluate if exposure to 5-alpha-reductase inhibitors (5-ARIs) modifies the effect of MRI for the diagnosis of clinically significant Prostate Cancer (csPCa) (ISUP Gleason grade ≥ 2).
methodsThis study is a multicenter cohort study including patients undergoing prostate biopsy and MRI at 24 institutions between 2013 and 2022. Multivariable analysis predicting csPCa with an interaction term between 5-ARIs and PIRADS score was performed. Sensitivity, specificity, and negative (NPV) and positive (PPV) predictive values of MRI were compared in treated and untreated patients.
results705 patients (9%) were treated with 5-ARIs [median age 69 years, Interquartile range (IQR): 65, 73; median PSA 6.3 ng/ml, IQR 4.0, 9.0; median prostate volume 53 ml, IQR 40, 72] and 6913 were 5-ARIs naïve (age 66 years, IQR 60, 71; PSA 6.5 ng/ml, IQR 4.8, 9.0; prostate volume 50 ml, IQR 37, 65). MRI showed PIRADS 1-2, 3, 4, and 5 lesions in 141 (20%), 158 (22%), 258 (37%), and 148 (21%) patients treated with 5-ARIs, and 878 (13%), 1764 (25%), 2948 (43%), and 1323 (19%) of untreated patients (p < 0.0001). No difference was found in csPCa detection rates, but diagnosis of high-grade PCa (ISUP GG ≥ 3) was higher in treated patients (23% vs 19%, p = 0.013). We did not find any evidence of interaction between PIRADS score and 5-ARIs exposure in predicting csPCa. Sensitivity, specificity, PPV, and NPV of PIRADS ≥ 3 were 94%, 29%, 46%, and 88% in treated patients and 96%, 18%, 43%, and 88% in untreated patients, respectively.
conclusionsExposure to 5-ARIs does not affect the association of PIRADS score with csPCa. Higher rates of high-grade PCa were detected in treated patients, but most were clearly visible on MRI as PIRADS 4 and 5 lesions.
trial registrationThe present study was registered at ClinicalTrials.gov number: NCT05078359.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.